

Figure 1


PBS
74.57%
0.5%
2.58%
22.35%
CtxB
95.08%
0.6%
1.91%
2.41%
EtxB(G33D)
74.96%
0.8%
3.93%
20.31%
EtxB
93.18%
0.94%
4.18%
1.71%
CtxB(E51A)
75.48%
0.82%
3.56%
20.15%
CtxB(V52A)
90.82%
0.61%
2.49%
6.07%
CD4 FITC
CD8 PE

Figure 2A

CtxB(P53A)



CtxB(G54A)



CtxB(S55A)



CtxB(Q56A)



CtxB(H57A)



CtxB(I58A)



Figure 2B


EtxB
EtxB(G33D)
CtxB
CtxB(E51A)
CtxB(V52A)
CtxB(P53A)
Events
FL1-Height

Figure 3A


CtxB(G54A)
CtxB(S55A)
CtxB(Q56A)
CtxB(H57A)
EtxB(H57S)
CtxB(I58A)
Events
FL1-Height

Figure 3B


7000
6000
5000
4000
3000
2000
1000
0
End point titre
P = 0.001
EtxB
EtxB(H57S)

Figure 4


150000
100000
50000
0
End point titre
1. Ova
2. EtxB
3. CtxB
4. EtxB + Ova
5. CtxB + Ova
6. EtxB(H57S) + Ova
7. CtxB(H57A) + Ova
1 2 3 4 5 6 7

Figure 5


Percentage CD8+ T-cells
26
25
24
23
22
21
20
0
5
10
15
20
Synthetic peptide (μM)
Synthetic peptide
Control peptide

Figure 6